Sixty Degrees Pharmaceuticals and Tufts Medical Center Announce Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention
23. Dezember 2024 08:57 ET
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharma and Tufts MC partner to develop tafenoquine for babesiosis, co-own patents, and aim for FDA approval to address unmet medical needs.
Tiziana Life Sciences Announces FDA Allowance for Additional Twenty Patients to be Enrolled in the Intranasal Foralumab Multiple Sclerosis Expanded Access Program
23. April 2024 07:00 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, April 23, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
Tiziana Life Sciences Announces Updated Clinical and PET Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients
08. Januar 2024 07:00 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough neuro-immunomodulation therapies,...
ideaPoint and WideTrial Launch Global Expanded Access Platform for COVID-19 Medicines
31. März 2020 07:00 ET
|
Anaqua
BOSTON, March 31, 2020 (GLOBE NEWSWIRE) -- Anaqua’s ideaPoint, a provider of medical affairs and innovation management solutions, today announced a strategic partnership with clinical data company...
Spend on HEOR Studies Expected to Grow at 9.7% Through 2020
19. Juli 2016 10:30 ET
|
Industry Standard Research
CARY, NC--(Marketwired - July 19, 2016) - Industry Standard Research has released a new report, "Late Phase Study Trends and Market Outlook (2016-2020)," containing findings focused on current...